Abstract Library

#2245 Metastatic VIPOMA, Co-Secreting Insulin, with Complete Response to Lanreotide Combined with Capecitabine and Temozolamide

Introduction: VIPomas are rare neuroendocrine tumors (NETs) associated with vasoactive intestinal polypeptide (VIP) hypersecretion causing watery diarrhea, hypokalaemia and achlorhydria. They originate mostly in the pancreas and 60-80% are malignant. Hormonal co-secretion is rarely reported.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Marques B

Authors: Marques B, Martins R, Ribeiro J, Couto J, Ferrão H,

Keywords: vipoma, neuroendocrine, lanreotide, capecitabine, temozolamide,

#1401 Everolimus (EV) Plus Somatostatin Analog (SSA) Administered Before or After Chemotherapy (CT) or PRRT in Advanced G1-G2 Neuroendocrine Tumor (NET): A Single Center Experience

Introduction: In metastatic NET G1-G2 progressed after SSA, many treatment are appropriated including EV, CT and PRRT. However, there are no studies guiding the appropriate sequence of treatments.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Marconcini R

Authors: Marconcini R, Ricci S, Antonuzzo A, Luca G, Vasile E,

Keywords: everolimus SSA,

#475 Methylguanine DNA Methyl Transferase (MGMT) Expression Predicts Response to Temozolamide in Patients with Digestive Neuroendocrine Tumors (NETs)

Introduction: Temozolomide (TEM) is an oral drug with encouraging results in pancreatic NETs (PNETs). MGMT tumor deficiency seems to be correlated with higher treatment efficacy.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Hentic O, Cros J, Rebours V, Zappa M, Maire F,

Keywords: neuroendocrine tumor, treatment, temozolomide, MGMT,

#460 Treatment of Unresectable Metastatic GEP NETs: Data From a Prospective Observational Unicentric Study

Introduction: In 2010 Everolimus, Sunitinib and Capecitabine plus Temozolamide confirmed efficacy in NETs.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Fonseca P, Galvan J, Gutierrez E, Álvarez C, Pérez Q,

Keywords: gep-net, SSA, Everolimus, Sunitinib, Temozolomide, Capecitabine,

#241 One-year Response to Everolimus in a Case of Advanced Pancreatic NET

Introduction: A stage IV pancreatic NET (30 mitoses/10 PF and Ki-67 index=40%) with liver and peritoneal metastases was diagnosed in a 35-year-old woman in June 2008. Characteristics: ECOG2 and CgA 1701 ng/ml.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: J Fonseca P, Vietez J, Galvan J, Crespo G, Astudillo A,

Keywords: pancreatic neuroendocrine tumor, Everolimus, Somatostatin Analogues, chemotherapy,